BiotechTube

QCZ484 + Placebo

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Mild Hypertension

Conditions

Mild Hypertension

Trial Timeline

Mar 8, 2023 → Jul 1, 2025

NCT ID
NCT06905327

About QCZ484 + Placebo

QCZ484 + Placebo is a phase 1 stage product being developed by Novartis for Mild Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT06905327. Target conditions include Mild Hypertension.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT06905327Phase 1Completed

Competing Products

20 competing products in Mild Hypertension

See all competitors
ProductCompanyStageHype Score
Neurosteroid enantiomerOragenicsPhase 2
44
Ranirestat + PlaceboEisaiPhase 2/3
65
Aricept (donepezil hydrochloride) + placeboEisaiApproved
85
Donepezil HClEisaiApproved
85
Donanemab + AducanumabEli LillyPhase 3
77
PPAR alpha + Hydrochlorothiazide + PlaceboEli LillyPhase 2
52
ElagolixAbbVieApproved
85
AZD1446 + PlaceboAstraZenecaPhase 2
52
MEDI1814 for IV injection + MEDI1814 for Subcutaneous Injection + IV Placebo + Placebo for Subcutaneous InjectionAstraZenecaPhase 1
33
Fluticasone propionate (Flovent Diskus) 250 mcg + budesonide 400 mcgAstraZenecaApproved
85
AZD5213 + AZD5213 + AZD5213AstraZenecaPhase 2
52
budesonide/formoterol (Symbicort)AstraZenecaPhase 3
77
MK-8931MerckPhase 1
33
Montelukast to placebo + Placebo to montelukastMerckPre-clinical
23
Verubecestat 12 mg (Parts 1 and 2) + Verubecestat 40 mg (Parts 1 and 2)MerckPhase 3
77
Aliskiren + Hydrochlorothiazide + AmlodipineNovartisApproved
85
LCZ696 + SildenafilNovartisPhase 2
52
Rivastigmine PatchNovartisApproved
85
AFQ056NovartisPhase 1
33
CanakinumabNovartisPhase 2
52

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85